Deutsche Bank AG Takes $1.59 Million Position in Mineralys Therapeutics, Inc. $MLYS

Deutsche Bank AG acquired a new position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 58,877 shares of the company's stock, valued at approximately $1,589,000. Deutsche Bank AG owned about 0.07% of Mineralys Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in MLYS. State Street Corp grew its holdings in shares of Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company's stock worth $115,584,000 after buying an additional 1,881,976 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Mineralys Therapeutics by 6,097.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,325,120 shares of the company's stock worth $48,089,000 after purchasing an additional 1,303,737 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Mineralys Therapeutics by 6,012.8% in the fourth quarter. Janus Henderson Group PLC now owns 1,213,265 shares of the company's stock valued at $44,005,000 after purchasing an additional 1,193,417 shares during the period. RA Capital Management L.P. grew its position in shares of Mineralys Therapeutics by 19.1% in the third quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company's stock valued at $277,717,000 after purchasing an additional 1,176,470 shares during the period. Finally, Orbimed Advisors LLC boosted its stake in Mineralys Therapeutics by 109.4% in the 1st quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock worth $55,613,000 after buying an additional 1,072,500 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company's stock.

Insider Activity

In related news, Director Daphne Karydas sold 3,000 shares of the firm's stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $25.00, for a total value of $75,000.00. Following the transaction, the director directly owned 6,200 shares in the company, valued at approximately $155,000. This trade represents a 32.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $27.09, for a total transaction of $58,785.30. Following the completion of the transaction, the insider owned 51,384 shares in the company, valued at $1,391,992.56. This trade represents a 4.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 224,333 shares of company stock valued at $5,806,213 in the last quarter. 18.94% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

MLYS has been the subject of a number of research analyst reports. Zacks Research downgraded shares of Mineralys Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Thursday, August 13th. Wall Street Zen lowered shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 15th. Jefferies Financial Group reissued a "hold" rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. HC Wainwright reissued a "buy" rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a research note on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $49.33.

Mineralys Therapeutics Stock Performance

MLYS opened at $25.60 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 34.46 and a current ratio of 34.46. The company has a market cap of $2.26 billion, a PE ratio of -6.04 and a beta of 0.68. The stock has a 50-day moving average of $26.88 and a 200-day moving average of $27.17. Mineralys Therapeutics, Inc. has a 52-week low of $14.94 and a 52-week high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($2.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($2.30). As a group, equities research analysts forecast that Mineralys Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Want to see what other hedge funds are holding MLYS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source